SCHEMBL6786407

SCHEMBL6786407

CC(C)(C)OC(=O)N(CCSc1ccc(Br)cc1)CC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
SDCBP O00560 1/20 0.38
SDC2 P34741 1/20 0.38
HSP90AA1 P07900 1/20 0.37
KCNH2 Q12809 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
SSTR4 P31391 1/20 0.37
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
NFKB1 P19838 1/20 0.36
CASP3 P42574 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8348656 0.91 HSP90AA1 (0.36) L3MBTL1SDCBPSDC2HSP90AA1KCNH2
SCHEMBL6787040 0.85 SLC6A4 (0.36) L3MBTL1SDCBPSDC2SMN1; SMN2SSTR4
SCHEMBL3858652 0.79 HDAC3 (0.46) SMN1; SMN2SSTR4RAB9ANPC1KMT2A
SCHEMBL8348739 0.77 SLC6A4 (0.36) L3MBTL1SDCBPSDC2SSTR4RAB9A
SCHEMBL8344651 0.76 CYP19A1 (0.38) ALDH1A1MAPT
SCHEMBL2579003 0.75 CA14 (0.42) L3MBTL1SSTR4KMT2ALMNAMEN1
SCHEMBL7016547 0.74 HSP90AA1 (0.50) L3MBTL1SDCBPSDC2HSP90AA1KCNH2
SCHEMBL24483689 0.72 ALDH1A1 (0.39) L3MBTL1SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL2929114 0.72 MLYCD (0.38) HSP90AA1SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL203927 0.72 SSTR4 (0.32) L3MBTL1SMN1; SMN2SSTR4RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092498-A1 Substituted glycine derivatives for use as medicaments BLAKEMORE DAVID (GB) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092498-A1 Substituted glycine derivatives for use as medicaments GLRA1, GRM1, GPR6 L3MBTL1 1002/4885SDCBP 1058/4885SDC2 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.